ATHA_OUT_1 [2025-04-02 08:15:37 -0400] 2989 Bytes | 786 tokens | Cum: 786 tkns (9.83% of 8k)
==========================================================================

We're scouting for winners today. Its 8:15:36 AM on Wed Apr 02, 2025 -0400 and I'm looking at Athira Pharma (ATHA) up to 0.3169 from 0.27

Help me investigate to see if its got potential or just another dud. So, I pulled together a bunch of data for you to look over real fast.

--- COMPANY PROFILE ---
Company: Athira Pharma (ATHA)
IPO: 2020-09-18 (4 Years Ago)
Market Cap: $10,541,460
Shares Outstanding: 39,040,000
Industry: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Exchange: XNAS
Description: Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) is a small molecule drug candidate designed to enhance the activity of the neurotrophic hepatocyte growth factor (HGF) system; ATH-1020 a novel, orally available, next-generation small molecule drug candidate designed to positively modulate the neurotrophic HGF system; ATH-1105 is a novel, orally available, next-generation, small molecule drug candidate designed to positively modulate the neurotrophic HGF system.

Here's the first list of news for Athira Pharma:

C1 - Feb-27-25 04:05PM - Athira Pharma Reports Full Year 2024 Financial Results and Pipeline and Business Updates
C2 - Dec-06-24 05:30PM - Athira Pharma Presents Preclinical Data Highlighting Neuroprotective Effects of ATH-1105 in Models of ALS at Motor Neurone Disease Association's 35th International Symposium on ALS/MND
C3 - Nov-08-24 04:50AM - Athira exploring strategic alternatives after Alzheimers failure
C4 - Nov-07-24 04:05PM - Athira Pharma Reports Third Quarter 2024 Financial Results and Pipeline and Business Updates
C5 - Oct-22-24 07:00AM - Athira Pharma to Present Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton at the Clinical Trials on Alzheimer's Disease (CTAD) 2024 Meeting
C6 - Sep-17-24 09:00AM - Athira Pharma to Focus on Advancement of ATH-1105 for the Treatment of Neurodegenerative Diseases
C7 - Sep-04-24 11:40AM - Alzheimers Trial Failure Sends Athira Stock Down 75%
C8 - Sep-04-24 11:40AM 11:33AM - Athiras stock topples after Alzheimers drug flops in Phase II/III trial

ONLY 3 RULES for AI:
==============
1) I am a document retrieval system. You are the analyst-investigator.
2) You can request items from my lists to get more info on Athira Pharma (ATHA)
3) AFTER requesting and reading News and SEC filings you'll write a summary, set a score, high price target and headline.
Now, your response should be only 2 or 3 chars. You can say ex., C1, C2, etc., or NEX
The NEX command delivers the NEXt list of News/SEC/Metrics
There are several more lists that use our unified document retrieval system in subsequent prompts.
Your predictons will be compared to reality to rate your accuracy. Try to predict accurately. GOOD LUCK!
Please request a document, read, summarize and score. Say something like "C1".

ATHA_OUT_3 [2025-04-02 08:15:38 -0400] 1100 Bytes | 310 tokens | Cum: 1098 tkns (13.73% of 8k)
==========================================================================

Showing C1 (chunk 1 of 8): C1:
**Athira Pharma Reports Full Year 2024 Financial Results and Pipeline and Business Updates**
Date: Feb-27-25 04:05PM
Source: (GlobeNewswire)
URL: https://www.globenewswire.com/news-release/2025/02/27/3034294/0/en/Athira-Pharma-Reports-Full-Year-2024-Financial-Results-and-Pipeline-and-Business-Updates.html

February 27, 2025 16:05 ET| Source:Athira Pharma, Inc.Athira Pharma, Inc.

Completed healthy volunteer Phase 1 clinical study of ATH-1105 as a potential treatment for amyotrophic lateral sclerosis (ALS)

BOTHELL, Wash., Feb. 27, 2025 (GLOBE NEWSWIRE) --Athira Pharma, Inc.(NASDAQ: ATHA), a clinical stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today reported financial results for the year ended December 31, 2024, and provided recent pipeline and business updates.

“We look forward to the opportunity to

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

ATHA_OUT_5 [2025-04-02 08:15:39 -0400] 380 Bytes | 87 tokens | Cum: 1187 tkns (14.84% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

ATHA_OUT_7 [2025-04-02 08:15:42 -0400] 253 Bytes | 85 tokens | Cum: 1274 tkns (15.93% of 8k)
==========================================================================

Showing A1 (chunk 1 of 1): A1:
Document A1 not found. Only 0 articles available.

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

ATHA_OUT_9 [2025-04-02 08:15:45 -0400] 979 Bytes | 292 tokens | Cum: 1618 tkns (20.23% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2024-07-10T13:01:37Z - Athira (ATHA) Completes Dosing in Alzheimer's Study, Stock Up - Zacks Investment Research
B2 - 2024-06-12T11:00:00Z - Athira to Host Webinar Highlighting Potential for Fosgonimeton to Protect and Preserve Neuronal Health in Mild-to-Moderate Alzheimer’s Disease Patients
B3 - 2024-05-29T11:00:00Z - Athira Pharma to Participate in Upcoming June Conferences
B4 - 2024-05-17T21:00:00Z - Athira Pharma Announces Proposed Settlement of Stockholder Derivative Action
B5 - 2024-05-15T20:05:00Z - Athira Pharma Reports First Quarter 2024 Financial Results and Pipeline and Business Updates
B6 - 2024-04-15T11:00:00Z - Athira Pharma Appoints Javier San Martin, M.D., as Chief Medical Officer

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

ATHA_OUT_11 [2025-04-02 08:15:49 -0400] 732 Bytes | 203 tokens | Cum: 1823 tkns (22.79% of 8k)
==========================================================================

Showing B1 (chunk 1 of 1): B1:
**Athira (ATHA) Completes Dosing in Alzheimer's Study, Stock Up - Zacks Investment Research**Date: Unknown DateSource: Unknown SourceURL: https://www.zacks.com/stock/news/2299235/athira-atha-completes-dosing-in-alzheimers-study-stock-upAthira Pharma has dosed the last patient in the phase II/III LIFT-AD study evaluating its pipeline candidate, fosgonimeton, for the treatment of mild-to-moderate Alzheimer's disease. The study is designed to assess the treatment effects of fosgonimeton across multiple aspects of the disease.

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

ATHA_OUT_13 [2025-04-02 08:15:49 -0400] 1085 Bytes | 297 tokens | Cum: 2204 tkns (27.55% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S6 - 2025-02-27 10-K Item 7. Mgts Discussion and Analysis of Fin Cond and Results of Oper.

You should read the following managements discussion and analysis of financial condition and results of operations in conjunction with our CONS financial statements and notes ...

S7 - 2024-11-07 10-Q PART IFINANCI AL INFO

Item 1. Fin Sta tements (Unaudited)

Athira Pharma, Inc.

Condensed Consolida ted Balance Sheets

(in thousands, except share and per share amounts)

September 30,

December 31,

(unaudited)

Assets

Curr assets:

Cash and cash eq...

S8 - 2024-10-07 8-K Item 9.01 Fin Stmnts and Exhibits.

(d) Exhibits.

Exhibit No.

Description

10.1*

Separation Agrmt and Release between Andrew Gengos and Athira Pharma, Inc. dated October 3, 2024

10.2*

Separation Agrmt and Release between Rachel Lenington and Athira P...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

ATHA_OUT_15 [2025-04-02 08:15:57 -0400] 1098 Bytes | 223 tokens | Cum: 2429 tkns (30.36% of 8k)
==========================================================================

Showing S6 (chunk 1 of 6): S6:
Item 7. Managements Discussion and Analysis of Financial Condition and Results of Operations.

You should read the following managements discussion and analysis of financial condition and results of operations in conjunction with our consolidated financial statements and notes thereto included in Part II, Item 8 of this Annual Report on Form 10-K. This discussion and analysis and other parts of this report contain forward-looking statements based upon current beliefs, plans and expectations related to future events and our future financial performance that involve risks, uncertainties and assumptions, such as statements regarding our intentions, plans, objectives, expectations, forecasts and projections. Our actual results and the timing of selected events could differ materially from those anticipated in these forward-looking statements as a result of several factors, including tho

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

ATHA_OUT_17 [2025-04-02 08:16:07 -0400] 5269 Bytes | 1558 tokens | Cum: 4147 tkns (51.84% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

+---------------------+-----------------------+-------------------------+----------------------+
| Volume: 316,268 | Perf Month: -28.23% | Option/Short: Yes / Yes | Sales Y/Y TTM: - |
+---------------------+-----------------------+-------------------------+----------------------+
| Avg Volume: 206.15K | Perf Quarter: -50.90% | Short Float: 2.92% | ROE: -110.77% |
+---------------------+-----------------------+-------------------------+----------------------+
| Rel Volume: 1.48 | Index: - | Short Ratio: 5.05 | ROI: -212.38% |
+---------------------+-----------------------+-------------------------+----------------------+
| RSI (14): 27.36 | Market Cap: 10.54M | Short Interest: 1.04M | Sales Surprise: - |
+---------------------+-----------------------+-------------------------+----------------------+
| ATR (14): 0.04 | Shs Outstand: 39.04M | Beta: 3.06 | EPS Surprise: 0.00% |
+---------------------+-----------------------+-------------------------+----------------------+
| SMA20: -17.01% | Shs Float: 35.70M | Sales Q/Q: - | P/E: - |
+---------------------+-----------------------+-------------------------+----------------------+
| SMA50: -34.86% | Inst Own: 46.13% | Sales past 5Y: 0.00% | Earnings: Feb 27 AMC |
+---------------------+-----------------------+-------------------------+----------------------+
| SMA200: -77.52% | Insider Own: 8.55% | Employees: 26 | |
+---------------------+-----------------------+-------------------------+----------------------+
| Perf Week: -19.48% | Insider Trans: -1.65% | Debt/Eq: 0.03 | |
+---------------------+-----------------------+-------------------------+----------------------+

The next section covers any insider trading.
If this section may be blank due to no recent filings.

Inside Trans: Athira Pharma, Inc. (ATHA) by Worthington Mark (General Counsel and CCO) on 2025-03-03
- Stock Option (Right to Buy): 85895 shares at $0 (D)
- Restricted Stock Units: 57263 shares at $0 (D)

Inside Trans: Athira Pharma, Inc. (ATHA) by San Martin Javier (CHIEF MEDICAL OFFICER) on 2025-03-03
- Stock Option (Right to Buy): 111270 shares at $0 (D)
- Restricted Stock Units: 74180 shares at $0 (D)

Inside Trans: Athira Pharma, Inc. (ATHA) by Litton Mark James (President and CEO) on 2025-03-03
- Stock Option (Right to Buy): 333815 shares at $0 (D)
- Restricted Stock Units: 222543 shares at $0 (D)

Inside Trans: Athira Pharma, Inc. (ATHA) by CHURCH KEVIN (CHIEF SCIENTIFIC OFFICER) on 2025-03-03
- Stock Option (Right to Buy): 87845 shares at $0 (D)
- Restricted Stock Units: 58563 shares at $0 (D)

Inside Trans: Athira Pharma, Inc. (ATHA) by Renninger Robert (SVP, Finance and Accounting) on 2025-03-03
- Stock Option (Right to Buy): 58500 shares at $0 (D)
- Stock Option (Right to Buy): 73350 shares at $0 (D)
- Restricted Stock Units: 39000 shares at $0 (D)

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -109222000.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 0.27
Average Volume: 213167.5
30-Day High: 0.3792
30-Day Low: 0.27

[Detailed Financials: Q3 2024]
- Total Assets: $86,246,000.0
- Total Liabilities: $28,663,000.0
- Total Equity: $57,583,000.0
- Current Assets: $82,002,000.0
- Current Liabilities: $27,751,000.0

[Income Statement: Q3 2024]
- Revenue: $0.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -0.75

[Cash Flow Statement: Q3 2024]
- Net Cash Flow: $-23,100,000.0

[Detailed Financials: Q2 2024]
- Total Assets: $111,253,000.0
- Total Liabilities: $27,918,000.0
- Total Equity: $83,335,000.0
- Current Assets: $106,704,000.0
- Current Liabilities: $26,902,000.0

[Income Statement: Q2 2024]
- Revenue: $0.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -0.7

[Cash Flow Statement: Q2 2024]
- Net Cash Flow: $-73,900,000.0
==== END OF FINANCIAL REPORT ====

You are now requested to make a summary analysis.
Save explaining why you didn't have enough information for the final survey.

Now, complete this report with the following:

1) Brief Summary: explain your findings in succinct wording.
2) MARKET_SCORE: If you calculate a 92% likelihood of an upward moves, say: MARKET_SCORE[92]
3) PRICE_TARGET: If you think the high today will be 50% higher, add to the price.
Eg., If the current price is $5.00, add 50%. Thus, PRICE_TARGET[$7.50] -- It should be at or above the current price.
4) Provide a thought-provoking take, 6-10 words, to use for the headline of this news story.
Like this: AI_RPT_HEADLINE: [6-12 words headline for news story, distilled from summary]

1) Brief Summary, 2) MARKET_SCORE, 3) PRICE_TARGET, and 4) AI_RPT_HEADLINE

ATHA_OUT_19 [2025-04-02 08:16:10 -0400] 676 Bytes | 167 tokens | Cum: 4557 tkns (56.96% of 8k)
==========================================================================

Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More stock-specific news
-> X2 <- More SEC filings (10-K, 10-Q, 8-K) Financials, risk disclosures, and business changes
-> X3 <- More SEC Insider Trading (Form 3, 4, 5) Direct buys/sells from executives and institutions
-> X4 <- Broader sector & market news
-> X5 <- Your past analysis on similar companies (specify metrics)
-> X6 <- More financial metrics
-> X7 <- Your past analysis on this exact company
-> X8 <- Something altogether different (explain...)

ATHA_IN_21 [2025-04-02 08:16:10 -0400] 126 Bytes | 29 tokens | Cum: 4645 tkns (58.06% of 8k)
==========================================================================

====================================
[2025-04-02 08:16:10] # Analysis Completed
Elapsed Time: 34.00 seconds